Citigroup Inc Sc Pharmaceuticals Inc. Transaction History

Citigroup Inc

$217 Billion
Q3 2025

A detailed history of Citigroup Inc transactions in Sc Pharmaceuticals Inc. stock. As of the latest transaction made, Citigroup Inc holds 3,038 shares of SCPH stock, worth $17,225. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,038

Previous 13,335 77.22%

Holding current value

$17,225

Previous $50,000 66.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	$3.86 - $5.84 $39,746 - $60,134	-10,297 Reduced 77.22%	3,038 $17,000
Q2 2025 Aug 11, 2025	SELL	$2.02 - $4.27 $31,310 - $66,185	-15,500 Reduced 53.75%	13,335 $50,000
Q1 2025 May 12, 2025	SELL	$2.63 - $3.68 $9,673 - $13,535	-3,678 Reduced 11.31%	28,835 $75,000
Q4 2024 Feb 12, 2025	BUY	$3.14 - $4.53 $12,861 - $18,554	4,096 Added 14.41%	32,513 $115,000
Q3 2024 Nov 12, 2024	BUY	$4.12 - $5.51 $91,628 - $122,542	22,240 Added 360.05%	28,417 $129,000
Q2 2024 Aug 12, 2024	BUY	$3.51 - $5.21 $4,928 - $7,314	1,404 Added 29.42%	6,177 $26,000
Q1 2024 May 10, 2024	BUY	$4.86 - $6.39 $3,022 - $3,974	622 Added 14.98%	4,773 $23,000
Q4 2023 Feb 09, 2024	BUY	$4.7 - $6.63 $19,411 - $27,381	4,130 Added 19666.67%	4,151 $26,000
Q3 2023 Nov 09, 2023	SELL	$7.0 - $9.82 $70,721 - $99,211	-10,103 Reduced 99.79%	21 $0
Q2 2023 Aug 10, 2023	BUY	$8.94 - $11.74 $88,148 - $115,756	9,860 Added 3734.85%	10,124 $103,000
Q1 2023 May 11, 2023	BUY	$5.59 - $9.47 $22 - $37	4 Added 1.54%	264 $2,000
Q4 2022 Feb 09, 2023	BUY	$4.02 - $7.53 $1,045 - $1,957	260 New	260 $1,000

Others Institutions Holding SCPH

# of Institutions

Shares Held

31.9M

Call Options Held

757K

Put Options Held

View Full List

About scPharmaceuticals Inc.

Ticker SCPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,402,100
Market Cap $155M
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...

More about SCPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account